Diabetic Retinopathy Occurs in Pre-Diabetes

Diabetic Retinopathy Occurs in Pre-Diabetes

Home Products
A-K
Products
L-Z
Amazon Shopping Terms and Conditions MX GuardDog Spam Blocker View Cart
Live Search
Buy anything from eBay!

Diabetic Retinopathy Occurs in Pre-Diabetes

PR Newswire

SAN DIEGO, June 12, 2005 /PRNewswire via COMTEX/ -- Diabetic retinopathy has been found in nearly 8 percent of pre-diabetic participants in the Diabetes Prevention Program (DPP), according to a report presented today at the American Diabetes Association's 65th Annual Scientific Sessions.  Diabetic retinopathy was also seen in 12 percent of participants with type 2 diabetes who developed diabetes during the DPP.  No other long-term study has evaluated retinopathy in a population so carefully examined for the presence or development of type 2 diabetes.

"These findings reinforce the recommendation that patients with newly diagnosed type 2 diabetes should be screened for retinopathy," said Emily Chew, M.D., of the National Eye Institute, the part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services that funded the study.  "We advise good control of blood glucose, blood pressure, and cholesterol as well as regular eye exams," she added.

"Previous studies have not accurately defined when type 2 diabetes begins, so our understanding of the onset of diabetic eye disease has been limited.

Now we know that diabetic retinopathy does occur in pre-diabetes.  We're also seeing it early in the course of diabetes -- within an average of 3 years after diagnosis," noted Richard Hamman, M.D., DrPH, professor and chair, Department of Preventive Medicine and Biometrics, University of Colorado School of Medicine, and vice chair of the DPP.  "This adds to our understanding of the development of retinopathy and suggests that changes in the eye may be starting earlier and at lower glucose levels than we previously thought."

Pre-diabetes is a condition in which blood glucose levels are higher than normal but not high enough for a diagnosis of diabetes.  The condition is sometimes called "impaired fasting glucose (IFG)" or "impaired glucose tolerance (IGT)," depending on the test used to diagnose it.  People with pre-diabetes have an increased risk of developing type 2 diabetes, heart disease, and stroke.

Diabetic retinopathy, which begins with changes in the small vessels in the back of the eye, often leads to loss of vision.  Regular eye examinations to diagnose retinopathy are recommended for patients with diabetes because treatment with laser photocoagulation can often prevent blindness in more advanced cases.  Diabetic retinopathy is still the most common cause of blindness in adults.  For more information about diabetic retinopathy, see NEI's Diabetic Retinopathy.

"Certain retinopathy lesions are considered indicative of the presence of diabetes because they are the first retinal changes to develop in this disease," explained Dr. Hamman.  "Although the retinopathy seen in the DPP participants was at a very early stage and did not affect vision, eye changes typical for diabetes were found in 8 percent of our study population before they developed diabetes.  These observations may lead diabetes experts to reconsider the diagnostic thresholds used to define diabetes, which are based on levels of blood glucose associated with the development of eye, nerve and kidney complications of diabetes."

DPP study chair David Nathan, M.D., of Massachusetts General Hospital, pointed out that the retinopathy results are based on a random sample of only 12 percent of DPP participants, all of whom had impaired glucose tolerance, a form of pre-diabetes, when the study began.  "These initial findings confirm what other studies have suggested.  The complications of diabetes may begin before diabetes is diagnosed, at least by the current-day standards," he explained.  "Ideally, an expanded study of the remaining 88 percent of DPP Outcome Study participants might enable us to define more appropriate diagnostic thresholds."

About 18.2 million Americans have diabetes, a group of serious diseases marked by high blood glucose levels that result from defects in the body's ability to produce and/or use insulin.  Diabetes can lead to severely debilitating or fatal complications, such as heart disease, blindness, kidney disease, and amputations.  It is the fifth leading cause of death by disease in the United States.  Type 2 diabetes, which accounts for up to 95 percent of all diabetes cases, involves insulin resistance -- the body's inability to properly use its own insulin.  It usually occurs in overweight adults, but it has increasingly been seen in obese children and teens in recent years.

About 40 percent of U.S. adults ages 40 to 74 -- 41 million people -- have abnormal blood glucose levels without having diabetes.  Many will develop type 2 diabetes in the next 10 years.  (In the DPP, about 10 percent of participants in the placebo group developed diabetes each year.)  Once a person has type 2 diabetes, the risk of heart and blood vessel disease is 2 to 4 times that of people without diabetes.

DIABETES PREVENTION PROGRAM

The Diabetes Prevention Program was a major clinical trial in 3,234 people with impaired glucose tolerance.  The study's main results were announced in 2001 and reported in the Feb. 7, 2002 issue of the New England Journal of Medicine:  Losing 5 to 7 percent of body weight through diet and a modest, consistent increase in physical activity (e.g., walking 5 days a week 30 minutes a day) lowered the incidence of type 2 diabetes by 58 percent.  Treatment with metformin, an oral drug commonly used to treat diabetes, reduced the chances of developing diabetes by 31 percent.

The DPP was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and co-funded by other components of the NIH, the Centers for Disease Control and Prevention, and the Indian Health Service. The American Diabetes Association provided additional funding.  Sources of corporate support included Bristol-Myers Squibb, Parke-Davis, Merck and Company, Merck Medco, Hoechst Marion Roussel, Sankyo, Lifescan, Lipha Pharmaceuticals, Slimfast, Nike, and Health-O-Meter.

About 90 percent of DPP participants continue to be followed closely in the DPP Outcomes Study to examine the longer-term impact of the original treatment interventions.  All participants are given access to quarterly lifestyle group sessions, while those in the original intensive lifestyle group have access to additional lifestyle activities to help them stay on track.  The participants originally assigned to metformin therapy continue to have access to the drug.

RETINOPATHY FINDINGS

Three hundred two, or about 12 percent, of the DPP Outcome Study participants who had not developed diabetes during the study, and 588 of 876 participants who had developed diabetes, were selected to participate in the retinopathy study, funded by the NEI. To detect diabetic retinopathy, an evaluation of the fundus (inner lining of the eye) was performed with a special camera that provides a detailed look at the retina.  Small changes in the vessels, called microaneurysms and hemorrhages, signal the development and degree of retinopathy severity.

Participants with pre-diabetes and retinopathy typically had a small number of microaneurysms in the eye characteristic of early, mild retinopathy that is not yet linked to vision loss.  Those who had developed diabetes in the previous 1 to 5 years had slightly more severe retinopathy.  Higher average blood glucose levels and higher blood pressure were associated with the risk of developing retinopathy in the new-onset diabetic patients, similar to previous findings in people with longstanding diabetes who develop retinopathy.

In its "Be Smart About Your Heart:  Control the ABCs of Diabetes" campaign, the National Diabetes Education Program (NDEP), jointly sponsored by the NIH, the Centers for Disease Control and Prevention, and 200 partner organizations including the American Diabetes Association (ADA), encourages people with diabetes to control their blood glucose as well as their blood pressure and cholesterol.  By keeping all three as close to normal as possible, people with diabetes can live long, healthy lives.

NDEP's "Small Steps.  Big Rewards.  Prevent Type 2 Diabetes" campaign gives tips on lifestyle changes to prevent or delay type 2 diabetes.

The American Diabetes Association is the nation's leading voluntary health organization supporting diabetes research, information and advocacy.  Founded in 1940, the Association has offices in every region of the country, providing services to hundreds of communities.  For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383).  Information from both these sources is available in English and Spanish.

Late Breaking Clinical Trials Symposium:

SOURCE:  American Diabetes Association.  CONTACT: Diane Tuncer of the ADA, +1-703-299-5510; Joan Chamberlain of NIDDK, +1-301-496-3583.  Rosemary Janiszewski of NEI, +1-301-496-5248; NEWS ROOM June 10-14, 2005: Room 17, San Diego Convention Center, San Diego, CA, Voice: +1-619-525-6392, Fax:  +1-619-525-6400

URLs: http://www.prnewswire.com, http://www.diabetes.org, http://www.ndep.nih.gov, http://www.nei.nih.gov/health/diabetic/retinopathy.asp.

Natural/Alternative/Preventive measures to consider:  Diabetes Mellitus - Page 1 | Page 2 | Page 3 | Page 4

More Information:  Diabetes Mellitus Type 2, Exercise, Blood Sugar | Dietary Troubles - Obesity, Diabetes, Heart Disease |
Diabetes & Vitamin D |
Diabetes, Obesity Seen as Accelerated Aging | Diabetic Adult Lifestyles - Late Onset Diabetes |
Early Detection - Insulin Resistance

 

Enjoy the benefits of our flat rate shipping and handling!  You receive the same great service for the same shipping price whether you order one item or one hundred!

$5.97 - Within USA only - US Post Office  5-9 business days.

$29.77 - To Canada only (see warning information here) 5-9 business days to customs check point (the only way we ship - US Post Office).

$39.77 - Outside USA only
(see warning here) 7-10 business days to your country's customs check point (the only way we ship - US Post Office).

Save 8.25% on all purchases - Texans and everyone!

It's all tax free!  You will be able to review all charges before they are charged to you.

At checkout (after you click the Add button on any of the order pages), the billing address you enter must match the address where you receive your credit card (security effects).  The shipping address you enter does not have to match.

All orders placed by Noon Central Standard Time (CST) are shipped the same day.  PO Boxes Okay.

Payment by credit card is immediate.  Payment by check adds a few more business days -- as soon as funds clear.

We do not sell the information you give us to anyone.


Protecting Your Personal Information
:
We pledge a safe and worry-free shopping experience using the industry standard for Internet security, 128-bit Secure Sockets Layer (SSL) encryption (see an online payments diagram).  SSL scrambles your personal and credit card information as it travels the Internet during the checkout process.  We utilize the Authorize.Net payment gateway.  Your credit card information is encrypted and sent to an Authorize.Net transaction server.  This server sends the data through the network to the card's bank, using a secure, proprietary connection.  When complete, you will receive an approval or decline response.  At no point is your credit card information stored on our server.

For additional information regarding the privacy of your sensitive cardholder data, please read the Authorize.Net Privacy Policy.

SmartBodyz Nutrition Home Page
1000 West 10th, Suite 218
Fort Worth, Texas 76102
Local Telephone: 817-335-1982
Email: DG[at]SmartBodyz.com - replace [at] with @
(helps prevent spam)
Copyright 1996-2017, SmartBodyz Nutrition -- all rights reserved.

Credit Card Processing

Credit Card Processing

You can shop here with safety and confidence.  We have partnered with Authorize.Net, a leading payment gateway since 1996, to offer safe and secure credit card transactions.

The information and statements made throughout this web site have not been endorsed/evaluated by the Food and Drug Administration or any other governmental authority, unless otherwise specifically noted.  We do not offer products or services for the benefits or purpose of diagnosis, prescription for, treatment of, or claims to prevent, mitigate or cure any viral or disease condition or be free from side effects.  Please, seek the advice of a competent medical professional about anything you read on our site.

BlogBlogLinks | Testimonials | Privacy | RSS Feed